24.07 USD
+0.37 (+1.56%)
24.07 USD
0 (0%)
Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 192 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. PCRX is valued quite cheap, but it does not seem to be growing. With these ratings, PCRX could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
In the past year PCRX had a positive cash flow from operations.
PCRX had positive earnings in 4 of the past 5 years.
In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
PCRX has a Return On Assets of 1.65%. This is amongst the best in the industry. PCRX outperforms 82.29% of its industry peers.
Looking at the Return On Equity, with a value of 2.95%, PCRX belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
PCRX's Return On Invested Capital of 3.63% is amongst the best of the industry. PCRX outperforms 81.77% of its industry peers.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.30%. This is significantly below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
Looking at the Profit Margin, with a value of 2.99%, PCRX belongs to the top of the industry, outperforming 80.21% of the companies in the same industry.
PCRX has a better Operating Margin (8.88%) than 80.73% of its industry peers.
In the last couple of years the Operating Margin of PCRX has grown nicely.
PCRX has a better Gross Margin (79.17%) than 83.33% of its industry peers.
PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
PCRX has less shares outstanding than it did 1 year ago.
PCRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PCRX is higher compared to a year ago.
2.2 Solvency
PCRX has an Altman-Z score of 2.01. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.01, PCRX is in line with its industry, outperforming 59.90% of the companies in the same industry.
The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.03, PCRX belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, PCRX is doing worse than 61.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.01 |
ROIC/WACC0.47
WACC7.73%
2.3 Liquidity
PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX's Current ratio of 5.26 is fine compared to the rest of the industry. PCRX outperforms 66.15% of its industry peers.
A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.78, PCRX perfoms like the industry average, outperforming 57.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
Measured over the past years, PCRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.96% on average per year.
The Revenue for PCRX has decreased by -16.85% in the past year. This is quite bad
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
The Earnings Per Share is expected to grow by 7.17% on average over the next years.
The Revenue is expected to grow by 6.09% on average over the next years.
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y7.17%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y6.09%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PCRX is valuated reasonably with a Price/Earnings ratio of 8.10.
Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 92.19% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (26.15), we can say PCRX is valued rather cheaply.
The Price/Forward Earnings ratio is 7.27, which indicates a rather cheap valuation of PCRX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 92.71% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.22. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.1 | ||
| Fwd PE | 7.27 |
4.2 Price Multiples
PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.23% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 91.15% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.34 | ||
| EV/EBITDA | 6.91 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.58
EPS Next 2Y1.59%
EPS Next 3Y6.02%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.07
+0.37 (+1.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.55%
Inst Owner Change-5.56%
Ins Owners0.81%
Ins Owner Change-0.27%
Market Cap1.04B
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target37.74 (56.79%)
Short Float %17.24%
Short Ratio11.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)-1.07%
PT rev (3m)-1.07%
EPS NQ rev (1m)4.68%
EPS NQ rev (3m)5.08%
EPS NY rev (1m)0.7%
EPS NY rev (3m)1.33%
Revenue NQ rev (1m)-1.94%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.1 | ||
| Fwd PE | 7.27 | ||
| P/S | 1.44 | ||
| P/FCF | 8.34 | ||
| P/OCF | 7.32 | ||
| P/B | 1.42 | ||
| P/tB | 3.19 | ||
| EV/EBITDA | 6.91 |
EPS(TTM)2.97
EY12.34%
EPS(NY)3.31
Fwd EY13.76%
FCF(TTM)2.89
FCFY11.99%
OCF(TTM)3.29
OCFY13.66%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.58
Graham Number33.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 2.01 |
F-Score7
WACC7.73%
ROIC/WACC0.47
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y6.09%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year0.19%
EBIT Next 3Y7.79%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PACIRA BIOSCIENCES INC (PCRX) stock?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.1 and the Price/Book (PB) ratio is 1.42.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 6 / 10.